Can a new targeted drug boost Chemotherapy's power against pancreatic cancer?

NCT ID NCT07769502

NEW Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy can help people with pancreatobiliary cancers, including pancreatic ductal adenocarcinoma. Participants will receive either the new combination or standard care, and researchers will compare how well the tumors respond and how long people live without the cancer progressing. The study aims to find the best dose and see if the combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telisotuzumab adizutecan combined with gemcitabine and nab-paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for pancreatobiliary cancers, potentially improving response rates and extending survival.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or could cause significant side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA PANCREATOBILIARY CANCERS

Contacts and locations

Locations

Cancer Hospital - Chinese Academy of Medical Sciences /ID# 281737

Beijing, Beijing Municipality, 100021, China
McGill University Health Centre - Glen Site /ID# 285570

Montreal, Quebec, H4A 3J1, Canada
Roswell Park Cancer Institute /ID# 284461

Buffalo, New York, 14263, United States
West China Hospital of Sichuan University /ID# 281734

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.